Yervoy/Zelboraf Combo Trial Fails, But Sequential Study Continues
This article was originally published in The Pink Sheet Daily
Small Phase I melanoma study testing a combination of Zelboraf and Yervoy was closed early due to an unexpectedly high rate of liver toxicity, investigators report in letter to the editor of the New England Journal of Medicine. A sequential study of Yervoy and Zelboraf and other combination studies proceed as planned.
You may also be interested in...
The speed with which TG Therapeutics burst on the scene, along with the impressive potency and safety of its novel combinations of cancer drugs, has perhaps blinded observers to the unique business model that has carried it this far.
Combinations of checkpoint inhibitors and targeted drugs are said to hold the key to better, more durable results in the future. But recent studies highlighted some big challenges, like unexpected toxicities, prompting a call for more preclinical research to better predict winning combinations.
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.